AZN241108P71000
- 4.65
- +3.73+405.43%
AstraZeneca Newsroom
BofA Securities Maintains AstraZeneca(AZN.US) With Buy Rating
BMO Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $89
AstraZeneca (AZN) Gets a Sell From Deutsche Bank
AstraZeneca's Promising Obesity Treatment Advances Justify Buy Rating: Analyst Report
UBS Reaffirms Their Sell Rating on AstraZeneca (AZN)
J.P. Morgan Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Reaffirms Their Buy Rating on AstraZeneca (AZN)
AstraZeneca (AZN) Receives a Hold From Jefferies
AstraZeneca Cut to Hold From Buy by Intron Health
AstraZeneca Target Cut to GBP120 From GBP140 by Intron Health
Goldman Sachs: Buy rating on cspc pharma, the trade with astrazeneca is an important step in global expansion.
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $95
Goldman Sachs Sticks to Its Buy Rating for AstraZeneca (AZN)
Buy Rating on Arcus Biosciences for Innovative CcRCC Treatment and Strategic AstraZeneca Collaboration
AstraZeneca (AZN) Receives a Hold From Jefferies
AstraZeneca: Strong Sales and Robust Pipeline Underpin Buy Rating
Citi Sticks to Their Buy Rating for AstraZeneca (AZN)
Erste Group Downgrades AstraZeneca(AZN.US) to Hold Rating
AstraZeneca's Market Position and Drug Pipeline Sustain Buy Rating Despite TB01 Trial Results
AstraZeneca: Strong Oncology Pipeline Fuels Growth and Outperformance – Buy Rating Endorsed